ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 575

Association Of Psoriasis and Psoriatic Arthritis With Systemic Lupus Erythematosus

Ashwini Shadakshari1, Jianghong Yu1 and Andras Perl2, 1Medicine/Rheumatology, SUNY Upstate Medical University, Syracuse, NY, 2Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: SLE and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: There is a paucity of literature on the prevalence of psoriasis (Ps) and psoriatic arthritis (PsA) in patients with systemic lupus erythematosus (SLE). To determine whether there are overlaps among these autoimmune diseases, we investigated the prevalence of Ps and PsA in patients with SLE.

Methods: We examined the prevalence of Ps and PsA in 445 patients with SLE based on history, physical examination, laboratory and radiological studies performed between 01/01/1990 and 07/31/12. A diagnosis of psoriasis was made by a dermatologist or rheumatologist while the diagnosis of PsA was made on the basis of CASPER criteria (Arth Rheum 2006; 54: 2665). The diagnosis of SLE was based on ACR criteria (Arth Rheum. 1997; 40: 1725). Prevalence of SLE diagnostic criteria were compared between SLE patients with and without Ps (SLE/Ps+ and Ps-) and with and without PsA (SLE/PsA+ and PsA-). Statistical analyses were performed with chi-square test using Graphpad Prism software with p<0.05 considered significant.

Results: Among 445 patients with SLE, 23 (5.1%) had Ps, out of which 20, (4.5%) patients had PsA. In the general population, the prevalence of Ps and PsA are estimated to be 2% (Rev Bras Reumatol. 2012; 52: 630) and 0.25% (Rev Bras Reumatol. 2012;52:98), respectively. Therefore, the prevalence of PsA, but not Ps, was increased in SLE patients (p < 0.0001). The prevalence of malar rash, discoid rash, photosensitivity, and arthritis were increased while antiphospholipid antibodies were less common in SLE patient with concurrent Ps and PsA (Table 1). There was no significant association of Ps or PsA with seizures, psychosis, oral ulcers, serositis, proteinuria, anemia, leucopenia, thrombocytopenia, hemolytic anemia, anti-Sm, or anti-DNA.

Table 1. Prevalence of SLE diagnostic criteria in patients with (SLE/Ps+) and without psoriasis (SLE/Ps+) as well as in patients with (SLE/PsA+) and without psoriatic arthritis (SLE/PsA+) in a cohort of 445 SLE subjects. The data were analyzed with chi-square test.

 

 

Malar Rash

Discoid Rash

Photosensitivity

Arthritis

APLA

SLE/Ps+

Present

11

4

13

21

1

 

Absent

12

19

10

2

22

SLE/Ps-

Present

118

21

142

211

108

 

Absent

304

401

280

211

314

p value

 

0.0409

0.0118

0.025

0.0001

0.021

 

 

 

 

 

 

 

SLE/PsA+

Present

10

4

12

20

1

 

Absent

10

16

8

0

19

SLE/PsA-

Present

119

21

143

213

108

 

Absent

306

404

282

212

317

p value

 

0.0341

0.0043

0.0156

 <  0.0001

0.038

Conclusion: PsA has increased prevalence in patients with SLE. Subjects with overlapping Ps and PsA may represent a distinct clinical entity within SLE.


Disclosure:

A. Shadakshari,
None;

J. Yu,
None;

A. Perl,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-psoriasis-and-psoriatic-arthritis-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology